Transparency Market Research

Primary Immunodeficiency Diseases Market to Accumulate Revenues Worth US $7.5 Bn by 2023-End as Healthcare Facilities Improve

 

Albany, NY -- (SBWIRE) -- 05/09/2019 -- Primary Immunodeficiency Diseases Market: Key Insights

In response to the rising incidence of antibody diseases, Transparency Market Research (TMR) forecasts the global primary immunodeficiency market to surge at 6.1% CAGR between 2015 and 2023. Developed regions such as Europe and North America are predominantly contributing to the growth witnessed by this market. The consistent approval of novel therapeutic options for primary immunodeficiency diseases (PIDD) and extensive research and development investments by key players are likely to bolster opportunities for the market in the forthcoming years.

On the flip side, the absence of proper reimbursement and high cost of therapies will inhibit the market's growth trajectory to an extent. Nevertheless, with favorable government policies and funding for research and development in biopharma and pharmaceuticals, growth prospects for the market seem quite promising.

Obtain Report Details @

https://www.transparencymarketresearch.com/primary-immunodeficiency-disease-market.html

TMR expects the global PIDD market to reach US$7.5 bn by the end of 2023, from a valuation of US$4.3 bn in 2014.

Rising Uptake of Immunoglobulin (Ig) Replacement Therapy Expected in Near Future

By treatment, stem cell and gene therapy, antibiotic therapy, immunoglobulin (Ig) replacement therapy, and others make the key segments in the global PIDD market. Of these, immunoglobulin replacement has been in use for the treatment of chronic ailments for the past two decades. Due to the recent developments, it is also used for the treatment of partial antibody deficiency and combined immunodeficiencies. The segment therefore emerged dominant in the market in 2014. As per TMR, immunoglobulin replacement therapy will hold on to its position as the market leader through the forecast period.

Request for Sample Copy of Report @

https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=3137

Despite, Ig replacement therapy being the most widely accepted treatment among PIDD patients, the use of antibiotics as an adjunct therapy is poised to surge in the near future. Some of the most commonly used antibiotics include penicillin, macrolides, cephalosporins, fluoroquinolones, and tetracyclines.

The demand for stem cell and gene therapy is also expected to increase during the forecast period, which in turn will augment the demand for effective PIDD treatment.

Request Report Brochure @

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=3137

About Transparency Market Research
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us
Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: www.transparencymarketresearch.com